Indication
High-Risk
2 clinical trials
2 products
5 drugs
Clinical trial
Phase I Study of the Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Drug
cyclophosphamideProduct
NK cellsDrug
NaxitamabProduct
rIL-2Clinical trial
Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal CancerStatus: Recruiting, Estimated PCD: 2025-01-01
Drug
PD-1 antibodyDrug
mFOLFOX6Drug
UTD1